Kasumi-1Homo sapiens (Human)Cancer cell line
Also known as: KASUMI-1, Kasumi 1, KASUMI1, Kasumi1, KUSAMI-1, Kusami-1
Quick Overview
Kasumi-1 is a leukemia cell line with t(8;21) translocation, used in AML research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0589 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 7 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
| Race | asian |
Disease Information
| Disease | Childhood acute myeloid leukemia with maturation |
|---|---|
| Lineage | Myeloid |
| Subtype | Acute Myeloid Leukemia |
| OncoTree Code | AML |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000263_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | RUNX1 | RUNX1-RUNX1T1, AML1-ETO | - | - | PubMed=15843827, PubMed=11753612 |
| MutationSimple | KIT | p.Asn822Lys (c.2466T>A) (N818K) | Unspecified | - | Wistar |
| MutationSimple | RAD21 | p.Lys330Profs*6 (c.987insCCGG) | Unspecified | - | from parent cell line Kasumi-1 |
| MutationSimple | TP53 | p.Arg248Gln (c.743G>A) | Unspecified | Somatic mutation acquired during proliferation | PubMed=20575032 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.
Kohara A., Kaneko Y., Kawamura M.
Hum. Cell 33:868-876(2020).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N.
Blood 77:2031-2036(1991).
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Imaizumi M., Endo M., Takano N., Konno T.
Leukemia 10:102-105(1996).
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Aizawa Y., Ueda R., Seto M.
Jpn. J. Cancer Res. 89:712-718(1998).
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 24:255-262(2000).
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 25:275-278(2001).
Molecular characterization of genomic AML1-ETO fusions in childhood leukemia.
Dicks B.M., Wiencke J.K., Wiemels J.L.
Leukemia 15:1906-1913(2001).
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
Beghini A., Magnani I., Ripamonti C.B., Larizza L.
Hematol. J. 3:157-163(2002).
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Larizza L., Magnani I., Beghini A.
Leuk. Lymphoma 46:247-255(2005).
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Fioretos T.
Leukemia 19:1042-1050(2005).
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Dexter T.J., Ashworth A., Kearney L.
Genes Chromosomes Cancer 45:554-564(2006).
Scanning the human genome at kilobase resolution.";
Zhang M.Q., Wang S.M.
Genome Res. 18:751-762(2008).
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
Schwabe M., Lubbert M.
Leukemia 22:1792-1794(2008).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Differential cytogenomics and miRNA signature of the acute myeloid leukaemia Kasumi-1 cell line CD34+38- compartment.
Larizza L.
Leuk. Res. 34:1287-1295(2010).
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Reynolds C.P.
Pediatr. Blood Cancer 56:239-249(2011).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Haferlach T., Shirahige K., Miyano S., Ogawa S.
Nat. Genet. 45:1232-1237(2013).
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Holzmann K., Westhoff M.-A., Corbacioglu S., Debatin K.-M.
Exp. Hematol. 42:90-100(2014).
RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.
Aleinikova O.V., Grinev V.V.
Leuk. Res. 38:1102-1110(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.
J. Hematol. Oncol. 10:26.1-26.5(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerstberger T., Zuber J., Savarese F., Kraut N.
Oncogene 37:2687-2701(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).